English

Nile Therapeutics, Inc.

EDGAR

CAPR Quarterly report (10-Q) · filed 2026-08-14

Annual consolidated revenue for 2025: about Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 0, using the latest reported figures. The previous period, 2024, was about Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 22.27M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

57.8 thousand

2020 Q4 ·

Exact inputs and evidence

Revenue: 310250 Unit1 Source
Revenue: 252420 Unit1 Source

Operating margin

-7,229.02%

2020 Q4 · %

Exact inputs and evidence

Operating Income: -13689971 Unit1 Source
Operating Income: -9509431 Unit1 Source
Revenue: 310250 Unit1 Source
Revenue: 252420 Unit1 Source

Cash and cash equivalents: 20.9 million Unit_Standard_USD_Ci7MZcGKD0uRcDMOYOG-kQ 2026-06-30 Source
Exact value

20935187 Unit_Standard_USD_Ci7MZcGKD0uRcDMOYOG-kQ
Long-term debt including current maturities: Not available
Shares outstanding: 58.1 million Unit_Standard_shares_b93qgDAcmEO6lwqwjUd2Zw 2026-06-30 Source
Exact value

58108989 Unit_Standard_shares_b93qgDAcmEO6lwqwjUd2Zw

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2025-12-31
Operating income: 2 of 11 periods available· newest 2025-12-31
Net income: 2 of 11 periods available· newest 2025-12-31
Operating cash flow: 2 of 11 periods available· newest 2025-12-31
Capital expenditure: 2 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 22.27 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 22270465 = -22270465 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg

22270465 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Nile Therapeutics, Inc. · 2025-12-31 Nile Therapeutics, Inc. (edgar:1133869) Year-over-year change in Revenue: -22270465 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1267761 Filing: 000110465926029580 Input fundies:Revenue: 22270465 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1268732 Filing: 000110465926029580
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 64.58 million

Prior period

−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 40.47 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 105.04 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-105043946 − -40467186 = -64576760 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg

-40467186 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-105043946 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Nile Therapeutics, Inc. · 2025-12-31 Nile Therapeutics, Inc. (edgar:1133869) Year-over-year change in Net income: -64576760 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -105043946 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1508301 Filing: 000110465926029580 Input fundies:NetIncome: -40467186 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1427399 Filing: 000110465926029580
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 29.82 million

Prior period

−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 40 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 69.81 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-69811261 − -39995742 = -29815519 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg

-39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Nile Therapeutics, Inc. · 2025-12-31 Nile Therapeutics, Inc. (edgar:1133869) Year-over-year change in Operating cash flow: -29815519 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1559181 Filing: 000110465926029580 Input fundies:OperatingCashFlow: -39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1560251 Filing: 000110465926029580
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+148.9%

Prior period

Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 1.17 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2.9 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2904461 − 1166871 = 1737590 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg

1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Nile Therapeutics, Inc. · 2025-12-31 Nile Therapeutics, Inc. (edgar:1133869) Year-over-year change in Capital expenditure: 1737590 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1569232 Filing: 000110465926029580 Input fundies:CapitalExpenditure: 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1570227 Filing: 000110465926029580
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 0
Operating costs Derived Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 108.14 million
Operating income −Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 108.14 million
Tax, interest and other Derived −Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 3.1 million
Net income −Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 105.04 million

Cash

Operating cash flow −Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 69.81 million
Capital expenditure Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2.9 million
Free cash flow Derived −Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 72.72 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2024 Operating loss: operating costs were 291% of revenue.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2024 2024-01-01 – 2024-12-31	22270465	64833707 Derived	-42563242	-2096056 Derived	-40467186	-41162613 Derived	Source 2024-01-01 – 2024-12-31: 22270465 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Revenue Open source 2024-01-01 – 2024-12-31: -42563242 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -40467186 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Net Income Open source 2024-01-01 – 2024-12-31: -39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	108142130 Derived	-108142130	-3098184 Derived	-105043946	-72715722 Derived	Source 2025-01-01 – 2025-12-31: 0 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Revenue Open source 2025-01-01 – 2025-12-31: -108142130 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -105043946 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Net Income Open source 2025-01-01 – 2025-12-31: -69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg)	Source evidence
20242024-12-31	Revenue	22270465	Revenue: 22270465 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Year over year	No prior comparable period	Revenue: 22270465 Open source
20252025-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 22270465 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -191.1% 2024

Net margin -181.7% 2024

Free cash flow margin -184.8% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Operating margin	-191.1%	Operating Income: -42563242 Open source Revenue: 22270465 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -108142130 Open source Revenue: 0 Open source
20242024-12-31	Net margin	-181.7%	Net Income: -40467186 Open source Revenue: 22270465 Open source
20252025-12-31	Net margin	Not reported	Net Income: -105043946 Open source Revenue: 0 Open source
20242024-12-31	Free cash flow margin	-184.8%	Revenue: 22270465 Open source Operating Cash Flow: -39995742 Open source Capital Expenditure: 1166871 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -69811261 Open source Capital Expenditure: 2904461 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg -69.8M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg)	Source evidence
20242024-12-31	Operating cash flow	-39995742	Operating Cash Flow: -39995742 Open source
20252025-12-31	Operating cash flow	-69811261	Operating Cash Flow: -69811261 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg -72.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg)	Source evidence
20242024-12-31	Free cash flow	-41162613	Operating Cash Flow: -39995742 Open source Capital Expenditure: 1166871 Open source
20252025-12-31	Free cash flow	-72715722	Operating Cash Flow: -69811261 Open source Capital Expenditure: 2904461 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2024-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2024 2024-01-01 – 2024-12-31	−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 40.47 million Exact value Exact value: -40467186 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2024-01-01 – 2024-12-31: -40467186 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Net Income Open source Share or cite Citation for Net Income · Nile Therapeutics, Inc. · 2024-12-31 Nile Therapeutics, Inc. (edgar:1133869) Net Income: -40467186 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg&dimensions= Input fundies:NetIncome: -40467186 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1427399 Filing: 000110465926029580 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 40 million Exact value Exact value: -39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2024-01-01 – 2024-12-31: -39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nile Therapeutics, Inc. · 2024-12-31 Nile Therapeutics, Inc. (edgar:1133869) Operating Cash Flow: -39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg&dimensions= Input fundies:OperatingCashFlow: -39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1560251 Filing: 000110465926029580 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 1.17 million Exact value Exact value: 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2024-01-01 – 2024-12-31: 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Nile Therapeutics, Inc. · 2024-12-31 Nile Therapeutics, Inc. (edgar:1133869) Capital Expenditure: 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg&dimensions= Input fundies:CapitalExpenditure: 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1570227 Filing: 000110465926029580 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 41.16 million Calculation and evidence -39995742 − 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Exact free cash flow: -41162613 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2024-01-01 – 2024-12-31: -39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Nile Therapeutics, Inc. · 2024-12-31 Nile Therapeutics, Inc. (edgar:1133869) Free cash flow: -41162613 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39995742 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1560251 Filing: 000110465926029580 Input fundies:CapitalExpenditure: 1166871 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1570227 Filing: 000110465926029580 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 105.04 million Exact value Exact value: -105043946 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2025-01-01 – 2025-12-31: -105043946 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Net Income Open source Share or cite Citation for Net Income · Nile Therapeutics, Inc. · 2025-12-31 Nile Therapeutics, Inc. (edgar:1133869) Net Income: -105043946 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg&dimensions= Input fundies:NetIncome: -105043946 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1508301 Filing: 000110465926029580 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 69.81 million Exact value Exact value: -69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2025-01-01 – 2025-12-31: -69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nile Therapeutics, Inc. · 2025-12-31 Nile Therapeutics, Inc. (edgar:1133869) Operating Cash Flow: -69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg&dimensions= Input fundies:OperatingCashFlow: -69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1559181 Filing: 000110465926029580 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2.9 million Exact value Exact value: 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2025-01-01 – 2025-12-31: 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Nile Therapeutics, Inc. · 2025-12-31 Nile Therapeutics, Inc. (edgar:1133869) Capital Expenditure: 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg&dimensions= Input fundies:CapitalExpenditure: 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1569232 Filing: 000110465926029580 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 72.72 million Calculation and evidence -69811261 − 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Exact free cash flow: -72715722 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg 2025-01-01 – 2025-12-31: -69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Nile Therapeutics, Inc. · 2025-12-31 Nile Therapeutics, Inc. (edgar:1133869) Free cash flow: -72715722 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:03:21Z Snapshot: 4ea1d0d06b4afd4a5304952ce82d6973d4f3c841a6375d08e339e3defd6aa805 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1133869?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -69811261 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1559181 Filing: 000110465926029580 Input fundies:CapitalExpenditure: 2904461 Unit_Standard_USD_jOqfaqKs-Eu7F7OTeaaRrg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm#1569232 Filing: 000110465926029580 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

123 filings · 5,180 latest values · 5,170 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001133869, 1133869, CAPR, NLTX, edgar:1133869

Also known as CAPRICOR THERAPEUTICS, INC., CAPRICOR THERAPEUTICS, INC., NILE THERAPEUTICS, INC., Nile Therapeutics, Inc., SMI PRODUCTS INC

Nile Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation